A Phase 4 clinical trial involving tirzepatide was updated on July 31, 2026. The trial, registered as NCT06374875 and titled "Fibrosis Lessens After Metabolic Surgery," is currently listed with a status of recruiting. Tirzepatide is an approved compound being studied in this Phase 4 setting.
According to the ClinicalTrials.gov record, the trial remains open for enrollment as of the listed date. No results have been posted for this trial at this time. The status update reflects only that the trial is actively seeking participants under its current phase designation.
No outcome data, efficacy findings, or safety conclusions are included in this update. The trial title references fibrosis in the context of metabolic surgery, but no interim or final findings have been reported as part of this recruiting status update.
Readers interested in tirzepatide can consult the compound overview for additional context on its approved uses and background.</body_markdown> <parameter name="sources">["https://clinicaltrials.gov/study/NCT06374875"]